Dr Kilian Kelly has over 20 years’ experience in biopharmaceutical research and development. He joined the Company in March 2014 as Vice President, Product Development, and was promoted to Chief Operating Officer in May 2019, before taking on the role of CEO & MD in July 2023. His previous appointments include Senior Director, Drug Development at Biota Pharmaceuticals (NASDAQ: BOTA), Vice President, Regulatory and Clinical at Mesoblast Limited (ASX:MSB), and positions with Kendle International (now Syneos Health; NASDAQ: SYNH), Amgen (NASDAQ: AMGN) and AstraZeneca (LSE: AZN). Dr Kelly holds a Masters in Pharmacy from Robert Gordon University, Aberdeen and a PhD in Pharmaceutical Sciences from Strathclyde University, Glasgow. He is a registered pharmacist and a member of the Royal Pharmaceutical Society, the Australian Institute of Company Directors, the International Society for Cell and Gene Therapy and the International Society for Stem Cell Research. He also currently serves on the Industry Interface Committee of the Center for Commercialisation of Regenerative Medicine (CCRM) Australia.

Dr Airey is an accomplished biopharmaceutical executive and physician with broad international experience in the successful development and commercialisation of pharmaceutical products including novel biological agents. She has been involved in the design and execution of multiple clinical trials from early through to late stage, encompassing a wide range of therapeutic categories in multiple geographies. Dr Airey is expected to join Cynata in October from CSL Limited where she is currently Director, Translational Development. Previously Dr Airey was a Clinical Development Physician at Seqirus, a CSL company, and earlier held a range of medical positions within biotech, pharmaceutical and clinical research companies. Her career path has led to her playing important roles in the market approvals of several drug products.